Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer.
NCT06923020 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-04-11
Summary
In patients with advanced gastrointestinal cancers, malnutrition can lead to increased incidence of adverse events during the peri-chemoradiotherapy period, reduced treatment tolerance, lower completion rates of therapy, compromised efficacy and quality of life, and ultimately shortened survival. Currently, immunotherapy represented by PD-1 inhibitors has become a cornerstone in the treatment of advanced gastrointestinal cancers. Nutritional status plays a critical role in malignancies, with the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score being particularly important for assessing nutritional conditions in cancer patients. Gastrointestinal cancers, as a group of heterogeneous tumors with distinct morphological and molecular genetic features, are closely linked to nutritional status. Peripheral blood cell profiles reflect the inflammatory impact of malignancies and immune responses in patients, which are crucial for determining treatment responses and clinical outcomes to enable early stratification, intervention, and monitoring. Therefore, this study aims to explore the clinical significance of nutrition-related prognostic indicators in immunotherapy by evaluating nutritional status and comparing treatment efficacy of first-line immune checkpoint inhibitors among advanced gastric cancer and esophageal cancer patients (including unresectable locally advanced, recurrent, or metastatic gastrointestinal cancers such as gastric/gastroesophageal junction adenocarcinoma and esophageal carcinoma) with different nutritional profiles.
Conditions
- Gastric Neoplasm
- Esophageal Adenosquamous Carcinoma
Interventions
- OTHER
-
Exposure: Nutritional Status
The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
- OTHER
-
Exposure: Nutritional Status
The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
Sponsors & Collaborators
-
Yongxu Jia
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2026-10-31
- Completion
- 2027-10-31
Countries
- China
Study Locations
More Related Trials
-
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
NCT06889402 ·Status: NOT_YET_RECRUITING
-
Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma
NCT04380480 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer
NCT03286920 ·Status: UNKNOWN
-
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
NCT06642857 ·Status: RECRUITING
-
Personalized Nutrition Counseling and Nutritional Status of Esophageal Cancer and HNSCC Patients Undergoing CCRT
NCT06829095 ·Status: RECRUITING
-
Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC
NCT04759235 ·Status: UNKNOWN
-
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NCT04688801 ·Status: RECRUITING ·Phase: NA
-
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
NCT02399306 ·Status: COMPLETED ·Phase: PHASE3
-
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
NCT04821778 ·Status: RECRUITING ·Phase: PHASE3
-
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
NCT06190847 ·Status: RECRUITING
-
Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer
NCT02375997 ·Status: UNKNOWN ·Phase: PHASE3
-
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06907602 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
NCT04513418 ·Status: RECRUITING ·Phase: PHASE3
-
Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
NCT03298204 ·Status: COMPLETED
-
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
NCT05800054 ·Status: RECRUITING ·Phase: NA
-
Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy
NCT06963593 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer
NCT04822103 ·Status: COMPLETED
-
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT06888531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
NCT06840704 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
NCT05777707 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
NCT04207918 ·Status: COMPLETED ·Phase: PHASE2
-
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
NCT06086457 ·Status: RECRUITING ·Phase: PHASE3
-
Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus
NCT01225523 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT05740995 ·Status: RECRUITING